Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

Core Viewpoint - Mineralys Therapeutics, Inc. is set to report its financial results for Q4 and the full year of 2025 on March 12, 2026, after market close, indicating a focus on transparency and investor communication [1]. Company Overview - Mineralys Therapeutics is a biopharmaceutical company dedicated to developing treatments for hypertension and related comorbidities, including chronic kidney disease (CKD) and obstructive sleep apnea (OSA) [3]. - The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor [3]. - Mineralys is headquartered in Radnor, Pennsylvania, and was founded by Catalys Pacific [3]. Investor Relations - A live conference call will be held on March 12, 2026, at 4:30 p.m. ET, with specific contact numbers provided for domestic and international participants [2]. - The conference call will also be accessible via a live webcast on the company's Investor Relations webpage [2]. Contact Information - Investor relations can be reached at investorrelations@mineralystx.com, and media inquiries can be directed to Melyssa Weible at Elixir Health Public Relations [4].